Turnstone Biologics Corp. (TSBX) Financial Statements (2024 and earlier)

Company Profile

Business Address 9310 ATHENA CIRCLE, SUITE 300
LA JOLLA, CA 92037
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:94,800
Cash and cash equivalents17,798
Short-term investments76,979
Other undisclosed cash, cash equivalents, and short-term investments23
Restricted cash and investments116
Receivables 194
Prepaid expense4,655
Other current assets2,812
Other undisclosed current assets(23)
Total current assets:102,554
Noncurrent Assets
Operating lease, right-of-use asset2,766
Property, plant and equipment6,352
Other noncurrent assets1,143
Total noncurrent assets:10,261
TOTAL ASSETS:112,815
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities677
Accounts payable36
Accrued liabilities641
Other undisclosed current liabilities11,293
Total current liabilities:11,970
Noncurrent Liabilities
Liabilities, other than long-term debt2,178
Other liabilities989
Operating lease, liability1,189
Total noncurrent liabilities:2,178
Total liabilities:14,148
Equity
Equity, attributable to parent98,667
Common stock23
Additional paid in capital275,521
Accumulated other comprehensive loss(119)
Accumulated deficit(176,758)
Total equity:98,667
TOTAL LIABILITIES AND EQUITY:112,815

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
Revenues19,306
Sublease income477
Gross profit:19,306
Operating expenses(78,338)
Other undisclosed operating loss 
Operating loss:(59,032)
Nonoperating income3,546
Loss from continuing operations before income taxes:(55,486)
Income tax benefit286
Net loss attributable to parent:(55,200)
Preferred stock dividends and other adjustments(39)
Net loss available to common stockholders, diluted:(55,239)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
Net loss:(55,200)
Other undisclosed comprehensive income294
Comprehensive loss, net of tax, attributable to parent:(54,906)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: